CD34 and acute myeloid leukemia: However, the status of refractory or relapse, LDH level, and karyotype did not significantly affect response of primary CD34+ AML cells to chidamide in combination with IDA (Table 4), indicating that the combination regimen of chidamide and IDA could rapidly diminish tumor burden in a patient with R/R AML.